This inventor holds 2 USPTO granted patents. Top assignees: Centre Hospitalier Universitaire De Saint-Étienne, Centre National De La Recherche Scientifique, Hospices Civils De Lyon. Active years: 2017-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:




Years Active: 2017-2020
Title: Jerome Marc Claude Honnorat: Trailblazer in Sensory Neuronopathy Innovations
Introduction: Jerome Marc Claude Honnorat is a prominent inventor based in Lyons, France, known for his significant contributions to the field of medical research. With two patents to his name, Honnorat has focused on advancing the diagnosis and treatment of acquired sensory neuronopathies.
Latest Patents: Honnorat's latest patents include groundbreaking work on "Fibroblast Growth Factor Receptors as Diagnostic Markers of Acquired Sensory Neuronopathies." This invention relates to diagnosing sensory neuronopathies (SNN) and offers innovative approaches for treating these disorders.
Career Highlights: Over his accomplished career, Jerome Marc Claude Honnorat has collaborated with esteemed institutions such as the National Institute of Health and Medical Research (Institut National de la Santé et de la Recherche Médicale) and the National Center for Scientific Research (Centre National de la Recherche Scientifique). His work at these reputable organizations has paved the way for technological advancements in healthcare.
Collaborations: Throughout his career, Honnorat has worked alongside respected colleagues, including Jean-Christophe Antoine and Jean-Philippe Camdessanche. These collaborations have fostered innovation and enhanced the research landscape in sensory neuronopathy.
Conclusion: Jerome Marc Claude Honnorat stands out as a key figure in the realm of medical innovation. His contributions through patented inventions not only aid in the diagnosis but also in the treatment of complex disorders, impacting the field of neurology significantly. As his career progresses, him and his collaborations continue to push the boundaries of medical science and technology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile